Drug Profile
AutoSynVax vaccine - Agenus/PureMHC
Alternative Names: ASV™ AGEN2017; Autologous-cancer-vaccine-Agenus; AutoSynVax™; HerpV-HSP70-tumour-peptide-loaded-vaccine-Agenus; Neoantigen vaccine - AgenusLatest Information Update: 28 Dec 2021
Price :
$50
*
At a glance
- Originator PhosImmune; Pure MHC
- Developer Agenus
- Class Cancer vaccines; Heat shock proteins; Monoclonal antibodies; Peptide vaccines; Synthetic vaccines
- Mechanism of Action Apoptosis stimulants; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer; Solid tumours
Most Recent Events
- 28 Dec 2021 No recent reports of development identified for phase-I development in Solid-tumours(Adjuvant therapy) in USA (SC, Injection)
- 03 Feb 2021 Agenus completes a phase I trial in Solid tumours (Adjuvant therapy) in the US (SC) (NCT03673020)
- 28 Feb 2020 No recent reports of development identified for phase-I development in Cancer(Late-stage disease) in USA (SC, Injection)